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Abstract 
Usually, celiac disease has a benign course, though the overall morbidity and mortality have 
increased. Treatment with a gluten-free diet restores the damaged intestinal mucosa. In rare 
cases a small bowel adenocarcinoma develops. Unfortunately, the clinical presentation is not 
always recognized and prognosis is bad. We present a 69-year-old man with a history of 
dermatitis herpetiformis who presented to our tertiary center for a second opinion for a 
suspected gastric motility disorder. This diagnosis was based on the combination of upper 
abdominal pain for over 2 years and repetitive episodes of vomiting. Immediately after 
referral, celiac disease was diagnosed and a gluten-free diet was started. In the next half 
year of follow-up, additional anemia and weight loss developed and eventually a small bowel 
adenocarcinoma was diagnosed. Revision of a small bowel follow-through, which had been 
performed 2 years earlier, showed that the tube had been positioned just distal from the 
process. Therefore, this diagnosis had not been made at that time. Unfortunately, curative 
therapy was not possible and the patient died a few months later. In conclusion, all patients 
with dermatitis herpetiformis have a gluten-sensitive enteropathy and should be treated 
with a gluten-free diet. Next to this it is important to notice that patients with celiac disease 
have an increased risk of developing a small bowel malignancy. Unexplained upper 
abdominal pain, weight loss and anemia should lead to additional investigations to exclude a 
small bowel malignancy in these patients. At last, the diagnosis of a small bowel carcinoma is 
difficult. Together with the radiologist, the optimal techniques for visualization of this 
malignancy should be considered. 
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Introduction 
Celiac disease is an inflammatory disorder in which the small intestine is damaged 
as a result of an excessive autoimmune response to gluten. Treatment consisting of a 
lifelong gluten-free diet restores the intestinal architecture. Once treated, celiac disease 
in general runs a benign course. However, the overall morbidity and mortality is 
moderately elevated in comparison to the general population. This is caused by the 
development of a number of associated disorders such as autoimmune diseases 
(hypothyroidism, diabetes, autoimmune hepatitis, alopecia), osteoporosis and 
inflammatory bowel disease [1–3]. 
One of the complications of celiac disease, with the largest implication for the 
patient’s survival, is the development of small bowel malignancies. Most studies report 
an increased risk of non-Hodgkin lymphoma in celiac disease, though the risk for the 
individual patient is still very low [2]. Some evidence suggests that a gluten-free diet 
may reduce lymphoma risk [4, 5], though two case-control studies that screened for 
silent, i.e. untreated, celiac disease in lymphoma patients reported a less clear clinical 
association than perhaps thought [6, 7].  
In addition, patients with celiac disease are at risk of developing a small bowel 
carcinoma [1, 8, 9]. Small bowel carcinomas are often overlooked in part because of 
their low prevalence, but also because diagnostic techniques such as video capsule 
and enteroscopy have only been recently developed. Most small bowel cancers are 
adenocarcinomas located between the duodenum and the ligament of Treitz [10, 11]. 
Surgical resection is the key therapy to obtain a good survival, but despite these 
measures the prognosis is dismal, with a 5-year survival rate of approximately 28% 
[12]. Earlier detection favors the chance of a good prognosis. It is unclear though 
whether earlier detection of celiac disease prevents the development of small bowel 
carcinoma. 
In this case report we want to raise the clinicians’ awareness for this silent killer in 
celiac disease and present the pitfalls in the clinical recognition as well as diagnosis of a 
small bowel adenocarcinoma. 
Case Report 
A 69-year-old male was referred to our tertiary center for a second opinion for a gastric motility 
disorder. His medical history revealed a dermatitis herpetiformis diagnosed 15 years previously 
which responded to Dapsone. In the two preceding years, he had been investigated in another center 
because of prolonged upper abdominal pain and vomiting. Initially anemia (Hb 7.6 mmol/l) attributed 
to a benign ventricular ulcer were diagnosed and treated. Due to persisting complaints, additional 
investigations were performed. Laboratory parameters were normal and a duodenoscopy, duodenal 
biopsies, an abdominal ultrasound, colonoscopy, an abdominal CT scan and a small bowel enteroclysis 
showed no abnormalities apart from a raised but decreasing ESR (from 76 to 59 mm/h) and a 
diverticular colon. Just prior to referral to our center, he developed severe vomiting and gastric 
retention. A motility disorder was considered and metoclopramide and erythromycin were 
prescribed. 
The patient was referred to our tertiary center for further analysis. Apart from vomiting and pain 
following meals he had no other symptoms. A few years earlier his BMI had decreased from obese to 
normal. Since then, his weight had been stable over the last year. Physical examination showed no 
abnormalities. Laboratory investigations showed a slightly raised ESR (25 mm/h), increased ALT 
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(127 U/l) and vitamin B12 deficiency. Revision of the small bowel follow-through and CT scan did not 
show any abnormalities. A new duodenoscopy was performed (fig. 1a). Duodenal histology showed 
partial villous atrophy (Marsh 3a), and celiac disease was diagnosed. The patient was referred to a 
dietician to start a gluten-free diet and vitamin B12 therapy was initiated. 
For almost half a year, the patient was free of complaints. Then his upper abdominal pain 
resumed. New duodenal biopsies excluded refractory celiac disease. Upon follow-up he suffered from 
involuntary weight loss. Three months later he presented with a palpable mass in the abdomen and 
anemia (Hb 6.9 mmol/l). A video capsule followed by a single balloon enteroscopy revealed a large 
process at the duodenal-jejunal junction (fig. 1b, c). The lesion appeared to be a poorly differentiated 
adenocarcinoma, partly of the signet cell type. A CT scan suggested mesenterial infiltration in close 
relation to the stomach and several enlarged lymph nodes. Laparotomy demonstrated an 
unresectable process with a close relation to the gastric wall, left kidney, aorta and pancreas. In view 
of these findings and given the unresectability, a palliative gastrojejunostomy was made. 
After surgery, the patient’s condition did not improve. A second CT showed an increase of the 
tumor mass and lymph node enlargement within 4 weeks. The patient died 2 months later. 
Discussion 
This case report gives rise to three important key messages of which we should be 
more aware in patients with (untreated) celiac disease. 
The first message concerns the fact that all patients with dermatitis herpetiformis 
have a gluten-sensitive enteropathy and that they should be advised to follow a 
gluten-free diet [13, 14]. We present a patient with long-existing dermatitis 
herpetiformis who developed a small bowel carcinoma 15 years after initial 
presentation. Our patient was never advised to follow a gluten-free diet, and in 
retrospect this may have been a contributing factor to the increased risk of small bowel 
carcinoma. The risk in dermatitis herpetiformis of developing additional autoimmune 
diseases is comparable with that in celiac disease, though the risk for developing a 
lymphoma is increased [15, 16]. Especially patients with dermatitis herpetiformis and 
autoimmune thyroiditis have a stronger predisposition to develop malignancies [16]. 
The second message underlines the importance of considering a small bowel 
adenocarcinoma in patients with (untreated) celiac disease who present with 
unexplained abdominal pain. However the problem is that patients often present with 
nonspecific complaints and that the awareness of the possibility of a small bowel 
adenocarcinoma is low because of the overall low incidence. In the spectrum of all 
possible malignancies, small bowel adenocarcinoma represents less than 0.5% of the 
cases. Only 2.5% of cancers in the digestive tract arise in the small bowel, of which  
30–40% present as an adenocarcinoma [10]. Why the small intestine is relatively 
protected against adenocarcinoma in comparison to the colon is unknown. Several 
hypotheses have been postulated, but all remain to be proven. Possible factors 
protecting the small bowel include a rapid turnover of the small intestine mucosal 
cells, a fast transit time and thus short exposure of the small bowel to food and 
possible carcinogens, a small bacterial load in the small intestine, a well-developed 
IgA-mediated immune system and an increased (protective) alkaline content of the 
small bowel [17]. More recently, Sanders et al. demonstrated that the small bowel 
produces less endogenous reactive oxidative species than the colon, resulting in a 
decrease in oxidative stress [18]. In (untreated) celiac disease the ongoing 
inflammatory reaction together with a more permeable mucosal membrane to 
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carcinogens and bacteria and the inability of the damaged epithelial cells to produce 
antioxidant enzymes may promote a malignant transformation [19]. Treatment of a 
small bowel adenocarcinoma is difficult and only based on surgical resection, with a 
5-year survival of 32.5% in case of resection [11]. There are some retrospective studies 
that suggest a benefit in survival after chemotherapy in patients with advanced small 
bowel adenocarcinoma [20, 21], though until now there are no specific guidelines 
because of the lack of randomized clinical trials. As such, it has a poor prognosis. 
At last, the diagnosis can easily be missed on conventional radiological 
investigations [22]. In the present case, the radiologists had not been made aware of 
the suspicion of a small bowel carcinoma. As a consequence, during the small bowel 
enteroclysis the tube was positioned just distal from the ligament of Treitz and thus 
distal from the malignant process. Since small bowel carcinoma in celiac disease often 
presents in the proximal small bowel, a position proximal from the ligament of Treitz is 
preferable. With knowledge of the diagnosis, a second revision of the small bowel 
enteroclysis, which had been performed 2 years earlier, demonstrated a subtle process 
close to the ligament of Treitz (fig. 2). 
Conclusion 
In conclusion, all patients with dermatitis herpetiformis should be regarded as celiac 
disease patients and a gluten-free diet should be advised. It is unclear though whether 
this will prevent the development of a small bowel malignancy. Also, we should be 
aware of the high risk of a small bowel carcinoma in celiac disease patients although a 
malignancy of the small intestine is rare. Unexplained upper abdominal pain, weight 
loss and anemia should lead to additional investigations to exclude a small bowel 
malignancy in these patients. At last, the diagnosis of a small bowel carcinoma is 
difficult. When considering this malignancy, one should make the radiologist aware of 
this suspicion. As a result, the most specific visualization techniques should be used. 
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Fig. 1. a The first duodenoscopy after referral to our center did not show any macroscopic alterations. 
Biopsies showed partial villous atrophy (Marsh 3a) and the diagnosis of celiac disease was set. 
b, c After 6 months abdominal pain developed again. A single balloon enteroscopy showed a large 
tumorous mass at the junction of the duodenum and the jejunum in which no further normal mucosa 
of the small intestine was recognized. 
 
 
 
Fig. 2. A second revision of the small bowel enteroclysis, which had been performed 2 years earlier, 
demonstrated a subtle process close to the ligament of Treitz. 
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